Disease-Modifying Therapies and Adherence in Multiple Sclerosis: Comparing Patient Self-Report with Pharmacy Records

Publisher： Karger

E-ISSN： 1423-0208|48|3-4|124-130

ISSN： 0251-5350

Source： Neuroepidemiology, Vol.48, Iss.3-4, 2017-07, pp. : 124-130

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Adherence to Disease-Modifying Therapies in Spanish Patients with Relapsing Multiple Sclerosis: Two-Year Interim Results of the Global Adherence Project

By  

European Neurology, Vol. 65, Iss. 2, 2011-01 ,pp. : 59-67

Karger

Access to resources Recommend Favorite

Efficacy of Disease-Modifying Therapies in Relapsing Remitting Multiple Sclerosis: A Systematic Comparison

By  

European Neurology, Vol. 60, Iss. 1, 2008-04 ,pp. : 1-11

Karger

Access to resources Recommend Favorite

Swiss Analysis of Multiple Sclerosis: A Multicenter, Non-Interventional, Retrospective Cohort Study of Disease-Modifying Therapies

By  

European Neurology, Vol. 70, Iss. 1-2, 2013-05 ,pp. : 35-41

Karger

Access to resources Recommend Favorite

Validation of a Self-Report Comorbidity Questionnaire for Multiple Sclerosis

By  

Neuroepidemiology, Vol. 35, Iss. 2, 2010-06 ,pp. : 83-90

Karger

Access to resources Recommend Favorite

Multiple Sclerosis-Associated Fatigue during Disease-Modifying Treatment with Natalizumab, Interferon-Beta and Glatiramer Acetate

By  

European Neurology, Vol. 65, Iss. 4, 2011-03 ,pp. : 231-232

Karger

Access to resources Recommend Favorite